Please login to the form below

Not currently logged in
Email:
Password:

GSK's personalised cancer drug Tafinlar set for European approval

Regulatory advisors recommend the melanoma drug be licensed

GSK - logo on building

GlaxoSmithKline's Tafinlar is on course to become the second BRAF inhibitor to reach the European market after a key regulatory committee recommended it be approved.

Tafinlar (dabrafenib) is under consideration as a treatment for adult patients with advanced (unresectable or metastatic) melanoma expressing a BRAF V600 gene mutation.

Tafinlar, which is given orally, has been shown to delay the progression of the disease and to improve the response rate compared with the chemotherapy dacarbazine.

The positive opinion from EMA's Committee for Medicinal Products for Human Use (CHMP) lines Tafinlar up to compete with Roche's Zelboraf (vemurafinib), which won EU approval last year.

Mutations of the protein kinase BRAF have been identified in about half of patients with metastatic melanoma, with the BRAF V600E mutation found in about 80 to 90 per cent of these.

These mutations cause the cell to make an abnormal protein that promotes cancer growth, and it's this abnormal protein that Tafinlar and Zelboraf seek to block, helping to slow down the growth and spread of tumours.

Such personalised medicines represent a significant therapeutic advance in melanoma treatment, follows decades when treatment options centred around cytotoxic chemo- and immunotherapy.

Melanoma is the sixth most common malignancy in men and the seventh most common in women, with almost 60,000 new cases diagnosed every year in Europe.

Cutaneous melanoma, the most common form of melanoma, is also the most aggressive type of skin cancer, with a median survival time for patients with stage IV melanoma of approximately six months.

Tafinlar won FDA approval in the US in May and now the CHMP recommendation puts the drug on course to receive full European approval by the European Commission within its usual decision timeline of three months.

1st July 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics